Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hagan

Showing results (121-130 of 274) with videos related to

Pageof 28
Sort By:
Vaccine|September 1, 2021
COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021Liesl M Hagan, Charles Dusseau, Michael Crockett, et al.
Alzheimer Disease and Associated Disorders|April 7, 1999
Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer typeD E Moss, P Berlanga, M M Hagan, et al.
British Journal of Pharmacology|October 1, 1991
Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345I J Beresford, P J Birch, R M Hagan, et al.
British Journal of Pharmacology|February 1, 1990
Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the ratR M Hagan, B J Jones, C C Jordan, et al.
International Journal of Peptide and Protein Research|December 1, 1993
Synthesis of a potent antagonist of substance P by replacing the CH2SCH3 and the alpha-carboxamide groups of the methionine at [Orn6]-SP6-11 by benzyl ester groupsK Karagiannis, G Stavropoulos, C Poulos, et al.
Health Affairs (Project Hope)|January 1, 1984
Health insurance for the unemployed: is federal legislation needed?A C Monheit, M M Hagan, M L Berk, et al.
Genetics|April 6, 2007
Suppression of the Schizosaccharomyces pombe cut12.1 cell-cycle defect by mutations in cdc25 and genes involved in transcriptional and translational controlVictor A Tallada, Alan J Bridge, Patrick A Emery, et al.
Nature Cell Biology|June 12, 2012
The S. pombe cytokinesis NDR kinase Sid2 activates Fin1 NIMA kinase to control mitotic commitment through Pom1/Wee1Agnes Grallert, Yvonne Connolly, Duncan L Smith, et al.
Molecular & Cellular Proteomics : MCP|November 5, 2014
Nic1 inactivation enables stable isotope labeling with 13C615N4-arginine in Schizosaccharomyces pombeAlejandro Carpy, Avinash Patel, Ye Dee Tay, et al.
The Joint Commission Journal on Quality Improvement|July 1, 1996
Adapting a statewide patient database for comparative analysis and quality improvementL S Rosen, K Schroeder, M Hagan, et al.
Pageof 28

Showing results (121-130 of 274) with videos related to

Sort By:
Pageof 28
Vaccine|September 1, 2021
COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021Liesl M Hagan, Charles Dusseau, Michael Crockett, et al.
Alzheimer Disease and Associated Disorders|April 7, 1999
Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer typeD E Moss, P Berlanga, M M Hagan, et al.
British Journal of Pharmacology|October 1, 1991
Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345I J Beresford, P J Birch, R M Hagan, et al.
British Journal of Pharmacology|February 1, 1990
Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the ratR M Hagan, B J Jones, C C Jordan, et al.
International Journal of Peptide and Protein Research|December 1, 1993
Synthesis of a potent antagonist of substance P by replacing the CH2SCH3 and the alpha-carboxamide groups of the methionine at [Orn6]-SP6-11 by benzyl ester groupsK Karagiannis, G Stavropoulos, C Poulos, et al.
Health Affairs (Project Hope)|January 1, 1984
Health insurance for the unemployed: is federal legislation needed?A C Monheit, M M Hagan, M L Berk, et al.
Genetics|April 6, 2007
Suppression of the Schizosaccharomyces pombe cut12.1 cell-cycle defect by mutations in cdc25 and genes involved in transcriptional and translational controlVictor A Tallada, Alan J Bridge, Patrick A Emery, et al.
Nature Cell Biology|June 12, 2012
The S. pombe cytokinesis NDR kinase Sid2 activates Fin1 NIMA kinase to control mitotic commitment through Pom1/Wee1Agnes Grallert, Yvonne Connolly, Duncan L Smith, et al.
Molecular & Cellular Proteomics : MCP|November 5, 2014
Nic1 inactivation enables stable isotope labeling with 13C615N4-arginine in Schizosaccharomyces pombeAlejandro Carpy, Avinash Patel, Ye Dee Tay, et al.
The Joint Commission Journal on Quality Improvement|July 1, 1996
Adapting a statewide patient database for comparative analysis and quality improvementL S Rosen, K Schroeder, M Hagan, et al.
Pageof 28